LLY

922.39

-1.51%↓

JNJ

186.29

-0.03%↓

UNH

324.11

+0.82%↑

NVS

126.28

-0.09%↓

ABT

126.19

+1.02%↑

LLY

922.39

-1.51%↓

JNJ

186.29

-0.03%↓

UNH

324.11

+0.82%↑

NVS

126.28

-0.09%↓

ABT

126.19

+1.02%↑

LLY

922.39

-1.51%↓

JNJ

186.29

-0.03%↓

UNH

324.11

+0.82%↑

NVS

126.28

-0.09%↓

ABT

126.19

+1.02%↑

LLY

922.39

-1.51%↓

JNJ

186.29

-0.03%↓

UNH

324.11

+0.82%↑

NVS

126.28

-0.09%↓

ABT

126.19

+1.02%↑

LLY

922.39

-1.51%↓

JNJ

186.29

-0.03%↓

UNH

324.11

+0.82%↑

NVS

126.28

-0.09%↓

ABT

126.19

+1.02%↑

Search

Maravai LifeSciences Holdings Inc (Class A)

Fermé

2.87 -0.69

Résumé

Variation du prix de l'action

24h

Actuel

Min

2.67

Max

2.88

Chiffres clés

By Trading Economics

Revenu

-17M

-70M

Ventes

547K

47M

Marge bénéficiaire

-147.345

Employés

560

EBITDA

-17M

-66M

Recommandations

By TipRanks

Recommandations

Achat

Prévisions sur 12 Mois

+49.83% upside

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

324M

1.1B

Ouverture précédente

3.56

Clôture précédente

2.87

Score Technique

By Trading Central

Confiance

Bullish Evidence

Maravai LifeSciences Holdings Inc (Class A) Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

7 nov. 2025, 21:06 UTC

Principaux Mouvements du Marché

JBS Down After Trump Calls for Probe into Meat-Packing Companies

7 nov. 2025, 22:36 UTC

Résultats

McDonald's Stock Challenged By a Tougher Economy, Analyst Says. Plus, Marriott, Snowflake, and More. -- Barrons.com

7 nov. 2025, 22:22 UTC

Résultats

The Score: GM, Tesla, Palantir, American Airlines and More Stocks That Defined the Week -- WSJ

7 nov. 2025, 22:03 UTC

Résultats

Constellation Software 3Q Rev $2.95B >CSU.T

7 nov. 2025, 22:03 UTC

Résultats

Constellation Software 3Q Net $210M >CSU.T

7 nov. 2025, 22:03 UTC

Résultats

Constellation Software 3Q EPS $9.89 >CSU.T

7 nov. 2025, 21:50 UTC

Market Talk

Financial Services Roundup: Market Talk

7 nov. 2025, 21:50 UTC

Market Talk

Health Care Roundup: Market Talk

7 nov. 2025, 20:59 UTC

Résultats

Palantir's CEO Says His Earnings Were the Best Ever. They Weren't Even the Best of the Week. -- Barrons.com

7 nov. 2025, 20:26 UTC

Market Talk

Natural U.S. Gas Futures Extend Rally to Three Weeks -- Market Talk

7 nov. 2025, 20:22 UTC

Résultats

Free-Spending Big Tech Dominates Earnings. As for the Rest: Don't Miss. -- Barrons.com

7 nov. 2025, 20:04 UTC

Market Talk

Oil Futures Close Choppy Week With Losses -- Market Talk

7 nov. 2025, 19:34 UTC

Market Talk

Gold Posts Small Gain for Week -- Market Talk

7 nov. 2025, 19:31 UTC

Market Talk
Acquisitions, Fusions, Rachats

Prices of Gas-Fired Power Plants Have Room to Grow -- Market Talk

7 nov. 2025, 19:17 UTC

Résultats

These Stocks Are Moving the Most Today: Tesla, Expedia, Take-Two, Block, Affirm, Sunrun, Globus Medical, JFrog, and More -- Barrons.com

7 nov. 2025, 19:09 UTC

Résultats

Wendy's Turnaround Won't Be Easy. Earnings, and the Stock, Tell the Story. -- Barrons.com

7 nov. 2025, 19:08 UTC

Résultats

KKR Defied Private-Equity Fundraising Slump in the Third Quarter -- WSJ

7 nov. 2025, 18:31 UTC

Market Talk

U.S. Oil RIg Count Unchanged at 414 -- Market Talk

7 nov. 2025, 17:27 UTC

Market Talk

EPA Announces New Exemptions to Biofuel Blending Rules -- Market Talk

7 nov. 2025, 17:20 UTC

Market Talk

Eli Lilly GLP-1 Deal with Trump Administration Provides Net Boost -- Market Talk

7 nov. 2025, 17:20 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

7 nov. 2025, 17:20 UTC

Market Talk

Financial Services Roundup: Market Talk

7 nov. 2025, 17:20 UTC

Market Talk

Health Care Roundup: Market Talk

7 nov. 2025, 17:17 UTC

Acquisitions, Fusions, Rachats

Satair Expects to Complete Purchase in Early 2026

7 nov. 2025, 17:17 UTC

Acquisitions, Fusions, Rachats

Satair: Deal Includes Unical's and ecube's Seven Operational Sites and Offices, With Combined 2024 Rev of $298M and Headcount of 413

7 nov. 2025, 17:15 UTC

Acquisitions, Fusions, Rachats

Airbus Unit Satair to Buy Unical Aviation From Platinum Equity

7 nov. 2025, 17:09 UTC

Market Talk

PENN Is Falling Further Behind Competitors -- Market Talk

7 nov. 2025, 16:49 UTC

Market Talk

Losing ESPN Partnership Will Hurt PENN -- Market Talk

7 nov. 2025, 16:24 UTC

Market Talk

OPEC+'s Output Hike Pause Comes Amid Excess Supply, Lower Spare Capacity -- Market Talk

7 nov. 2025, 16:17 UTC

Market Talk

Oil Market Faces Oversupply But "Glut" Might Be Overblown -- Market Talk

Comparaison

Variation de prix

Maravai LifeSciences Holdings Inc (Class A) prévision

Objectif de Prix

By TipRanks

49.83% hausse

Prévisions sur 12 Mois

Moyen 4.33 USD  49.83%

Haut 5 USD

Bas 4 USD

Basé sur 6 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat

6 ratings

4

Achat

2

Maintien

0

Vente

Score Technique

By Trading Central

2.02 / 2.115Support & Résistance

Court Terme

Bullish Evidence

Moyen Terme

Strong Bullish Evidence

Long Terme

No Evidence

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Maravai LifeSciences Holdings Inc (Class A)

Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as custom enzyme development and manufacturing and CleanCap capping technology. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody, and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, viral clearance prediction kits, and custom services. The company serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. The company was incorporated in 2020 and is headquartered in San Diego, California.
help-icon Live chat